Literature DB >> 29105657

Gait training after spinal cord injury: safety, feasibility and gait function following 8 weeks of training with the exoskeletons from Ekso Bionics.

Carsten Bach Baunsgaard1, Ulla Vig Nissen2, Anne Katrin Brust3, Angela Frotzler3, Cornelia Ribeill4, Yorck-Bernhard Kalke4, Natacha León5, Belén Gómez5, Kersti Samuelsson6, Wolfram Antepohl6, Ulrika Holmström7, Niklas Marklund7, Thomas Glott8, Arve Opheim8,9, Jesus Benito10, Narda Murillo10, Janneke Nachtegaal11, Willemijn Faber11, Fin Biering-Sørensen2.   

Abstract

STUDY
DESIGN: Prospective quasi-experimental study, pre- and post-design.
OBJECTIVES: Assess safety, feasibility, training characteristics and changes in gait function for persons with spinal cord injury (SCI) using the robotic exoskeletons from Ekso Bionics.
SETTING: Nine European rehabilitation centres.
METHODS: Robotic exoskeleton gait training, three times weekly over 8 weeks. Time upright, time walking and steps in the device (training characteristics) were recorded longitudinally. Gait and neurological function were measured by 10 Metre Walk Test (10 MWT), Timed Up and Go (TUG), Berg Balance Scale (BBS), Walking Index for Spinal Cord Injury (WISCI) II and Lower Extremity Motor Score (LEMS).
RESULTS: Fifty-two participants completed the training protocol. Median age: 35.8 years (IQR 27.5-52.5), men/women: N = 36/16, neurological level of injury: C1-L2 and severity: AIS A-D (American Spinal Injury Association Impairment Scale). Time since injury (TSI) < 1 year, N = 25; > 1 year, N = 27. No serious adverse events occurred. Three participants dropped out following ankle swelling (overuse injury). Four participants sustained a Category II pressure ulcer at contact points with the device but completed the study and skin normalized. Training characteristics increased significantly for all subgroups. The number of participants with TSI < 1 year and gait function increased from 20 to 56% (P = 0.004) and 10MWT, TUG, BBS and LEMS results improved (P < 0.05). The number of participants with TSI > 1 year and gait function, increased from 41 to 44% and TUG and BBS results improved (P < 0.05).
CONCLUSIONS: Exoskeleton training was generally safe and feasible in a heterogeneous sample of persons with SCI. Results indicate potential benefits on gait function and balance.

Entities:  

Mesh:

Year:  2017        PMID: 29105657     DOI: 10.1038/s41393-017-0013-7

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  33 in total

Review 1.  A systematic review of functional ambulation outcome measures in spinal cord injury.

Authors:  T Lam; V K Noonan; J J Eng
Journal:  Spinal Cord       Date:  2007-10-09       Impact factor: 2.772

2.  Motor and sensory recovery following incomplete tetraplegia.

Authors:  R L Waters; R H Adkins; J S Yakura; I Sie
Journal:  Arch Phys Med Rehabil       Date:  1994-03       Impact factor: 3.966

3.  Safety and tolerance of the ReWalk™ exoskeleton suit for ambulation by people with complete spinal cord injury: a pilot study.

Authors:  Gabi Zeilig; Harold Weingarden; Manuel Zwecker; Israel Dudkiewicz; Ayala Bloch; Alberto Esquenazi
Journal:  J Spinal Cord Med       Date:  2012-02-07       Impact factor: 1.985

Review 4.  Spinal cord injury medicine. 3. Rehabilitation phase after acute spinal cord injury.

Authors:  Steven C Kirshblum; Michael M Priebe; Chester H Ho; William M Scelza; Anthony E Chiodo; Lisa-Ann Wuermser
Journal:  Arch Phys Med Rehabil       Date:  2007-03       Impact factor: 3.966

5.  Assessing walking ability in subjects with spinal cord injury: validity and reliability of 3 walking tests.

Authors:  Hubertus J van Hedel; Markus Wirz; Volker Dietz
Journal:  Arch Phys Med Rehabil       Date:  2005-02       Impact factor: 3.966

6.  Psychophysical bases of perceived exertion.

Authors:  G A Borg
Journal:  Med Sci Sports Exerc       Date:  1982       Impact factor: 5.411

7.  The ReWalk powered exoskeleton to restore ambulatory function to individuals with thoracic-level motor-complete spinal cord injury.

Authors:  Alberto Esquenazi; Mukul Talaty; Andrew Packel; Michael Saulino
Journal:  Am J Phys Med Rehabil       Date:  2012-11       Impact factor: 2.159

8.  Voluntary driven exoskeleton as a new tool for rehabilitation in chronic spinal cord injury: a pilot study.

Authors:  Mirko Aach; Oliver Cruciger; Matthias Sczesny-Kaiser; Oliver Höffken; Renate Ch Meindl; Martin Tegenthoff; Peter Schwenkreis; Yoshiyuki Sankai; Thomas A Schildhauer
Journal:  Spine J       Date:  2014-04-04       Impact factor: 4.166

Review 9.  Challenges for defining minimal clinically important difference (MCID) after spinal cord injury.

Authors:  X Wu; J Liu; L G Tanadini; D P Lammertse; A R Blight; John L K Kramer; G Scivoletto; L Jones; S Kirshblum; R Abel; J Fawcett; E Field-Fote; J Guest; B Levinson; D Maier; K Tansey; N Weidner; W G Tetzlaff; T Hothorn; A Curt; J D Steeves
Journal:  Spinal Cord       Date:  2014-12-16       Impact factor: 2.772

10.  The combined effects of body weight support and gait speed on gait related muscle activity: a comparison between walking in the Lokomat exoskeleton and regular treadmill walking.

Authors:  Klaske Van Kammen; Annemarijke Boonstra; Heleen Reinders-Messelink; Rob den Otter
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

View more
  31 in total

1.  "Back at the same level as everyone else"-user perspectives on walking with an exoskeleton, a qualitative study.

Authors:  Gunn-Kristin Knudsen Thomassen; Vivien Jørgensen; Britt Normann
Journal:  Spinal Cord Ser Cases       Date:  2019-12-13

2.  Looking back on 2019.

Authors:  Lisa A Harvey
Journal:  Spinal Cord       Date:  2019-12       Impact factor: 2.772

3.  Incidental bilateral calcaneal fractures following overground walking with a wearable robotic exoskeleton in a wheelchair user with a chronic spinal cord injury: is zero risk possible?

Authors:  A Bass; S N Morin; M Vermette; M Aubertin-Leheudre; D H Gagnon
Journal:  Osteoporos Int       Date:  2020-01-13       Impact factor: 4.507

4.  Safety and feasibility of exoskeleton-assisted walking during acute/sub-acute SCI in an inpatient rehabilitation facility: A single-group preliminary study.

Authors:  Andrew D Delgado; Miguel X Escalon; Thomas N Bryce; William Weinrauch; Stephanie J Suarez; Allan J Kozlowski
Journal:  J Spinal Cord Med       Date:  2019-10-11       Impact factor: 1.985

Review 5.  Robotic Rehabilitation and Spinal Cord Injury: a Narrative Review.

Authors:  Marwa Mekki; Andrew D Delgado; Adam Fry; David Putrino; Vincent Huang
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

Review 6.  Wearable powered exoskeletons for gait training in tetraplegia: a systematic review on feasibility, safety and potential health benefits.

Authors:  Gonzalo Rodriguez Tapia; Ioannis Doumas; Thierry Lejeune; Jean-Gabriel Previnaire
Journal:  Acta Neurol Belg       Date:  2022-07-17       Impact factor: 2.471

7.  Effects of robotic-assisted gait training on the central vascular health of individuals with spinal cord injury: A pilot study.

Authors:  James Faulkner; Louis Martinelli; Kirsty Cook; Lee Stoner; Helen Ryan-Stewart; Eloise Paine; Helen Hobbs; Danielle Lambrick
Journal:  J Spinal Cord Med       Date:  2019-09-16       Impact factor: 1.985

8.  Feasibility of robotic exoskeleton ambulation in a C4 person with incomplete spinal cord injury: a case report.

Authors:  Robert M Lester; Ashraf S Gorgey
Journal:  Spinal Cord Ser Cases       Date:  2018-04-27

9.  Exoskeletal-assisted walking may improve seated balance in persons with chronic spinal cord injury: a pilot study.

Authors:  Chung-Ying Tsai; Pierre K Asselin; Eunkyoung Hong; Steven Knezevic; Stephen D Kornfeld; Noam Y Harel; Ann M Spungen
Journal:  Spinal Cord Ser Cases       Date:  2021-03-12

Review 10.  The Effects of Powered Exoskeleton Gait Training on Cardiovascular Function and Gait Performance: A Systematic Review.

Authors:  Damien Duddy; Rónán Doherty; James Connolly; Stephen McNally; Johnny Loughrey; Maria Faulkner
Journal:  Sensors (Basel)       Date:  2021-05-05       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.